Monte Rosa Net Worth
Monte Rosa Net Worth Breakdown | GLUE |
Monte Rosa Net Worth Analysis
Monte Rosa's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Monte Rosa's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Monte Rosa's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Monte Rosa's net worth analysis. One common approach is to calculate Monte Rosa's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Monte Rosa's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Monte Rosa's net worth. This approach calculates the present value of Monte Rosa's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Monte Rosa's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Monte Rosa's net worth. This involves comparing Monte Rosa's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Monte Rosa's net worth relative to its peers.
Enterprise Value |
|
To determine if Monte Rosa is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Monte Rosa's net worth research are outlined below:
| Monte Rosa generated a negative expected return over the last 90 days | |
| Monte Rosa has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 75.62 M. Net Loss for the year was (72.7 M) with loss before overhead, payroll, taxes, and interest of (37.24 M). | |
| Monte Rosa has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate ... |
Monte Rosa uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Monte Rosa Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Monte Rosa's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Monte Rosa Target Price Consensus
Monte target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Monte Rosa's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 8 | Strong Buy |
Most Monte analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Monte stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Monte Rosa Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationMonte Rosa Target Price Projection
Monte Rosa's current and average target prices are 5.80 and 16.00, respectively. The current price of Monte Rosa is the price at which Monte Rosa Therapeutics is currently trading. On the other hand, Monte Rosa's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On Monte Rosa Target Price
Know Monte Rosa's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Monte Rosa is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Monte Rosa Therapeutics backward and forwards among themselves. Monte Rosa's institutional investor refers to the entity that pools money to purchase Monte Rosa's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Aisling Capital Management Lp | 2024-12-31 | 1.5 M | Alphabet Inc | 2024-12-31 | 1.5 M | State Street Corp | 2024-12-31 | 1.1 M | Geode Capital Management, Llc | 2024-12-31 | 1 M | Citadel Advisors Llc | 2024-12-31 | 778.4 K | Marshall Wace Asset Management Ltd | 2024-12-31 | 499.5 K | Norges Bank | 2024-12-31 | 445.9 K | Vestal Point Capital Lp | 2024-12-31 | 425 K | Northern Trust Corp | 2024-12-31 | 377 K | Nea Management Company, Llc | 2024-12-31 | 7.7 M | T. Rowe Price Associates, Inc. | 2024-12-31 | 7.1 M |
Follow Monte Rosa's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 356.33 M.Market Cap |
|
Project Monte Rosa's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.17) | (0.17) | |
| Return On Capital Employed | (0.29) | (0.30) | |
| Return On Assets | (0.17) | (0.17) | |
| Return On Equity | (0.33) | (0.31) |
When accessing Monte Rosa's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Monte Rosa's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Monte Rosa's profitability and make more informed investment decisions.
Please note, the presentation of Monte Rosa's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Monte Rosa's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Monte Rosa's management manipulating its earnings.
Evaluate Monte Rosa's management efficiency
Monte Rosa Therapeutics has return on total asset (ROA) of (0.1366) % which means that it has lost $0.1366 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3615) %, meaning that it created substantial loss on money invested by shareholders. Monte Rosa's management efficiency ratios could be used to measure how well Monte Rosa manages its routine affairs as well as how well it operates its assets and liabilities. As of March 23, 2025, Return On Tangible Assets is expected to decline to -0.17. In addition to that, Return On Capital Employed is expected to decline to -0.3. The current year's Net Tangible Assets is expected to grow to about 327.7 M, whereas Total Assets are forecasted to decline to about 277.1 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.02 | 2.45 | |
| Tangible Book Value Per Share | 3.02 | 2.45 | |
| Enterprise Value Over EBITDA | (4.09) | (4.29) | |
| Price Book Value Ratio | 2.30 | 2.42 | |
| Enterprise Value Multiple | (4.09) | (4.29) | |
| Price Fair Value | 2.30 | 2.42 | |
| Enterprise Value | 331.4 M | 619.7 M |
Monte Rosa Therapeutics benefits from a management team that prioritizes both innovation and efficiency. We analyze these priorities to gauge the stock's future performance.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Monte Rosa insiders, such as employees or executives, is commonly permitted as long as it does not rely on Monte Rosa's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Monte Rosa insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Monte Rosa Corporate Filings
8K | 20th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
| 4th of February 2025 Other Reports | ViewVerify | |
F4 | 6th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Monte Rosa Earnings Estimation Breakdown
The calculation of Monte Rosa's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Monte Rosa is estimated to be -0.3221 with the future projection ranging from a low of -0.5 to a high of -0.13. Please be aware that this consensus of annual earnings estimates for Monte Rosa Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.5 Lowest | Expected EPS | -0.13 Highest |
Monte Rosa Earnings Projection Consensus
Suppose the current estimates of Monte Rosa's value are higher than the current market price of the Monte Rosa stock. In this case, investors may conclude that Monte Rosa is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Monte Rosa's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
| 9 | 77.45% | 0.27 | -0.3221 | -0.98 |
Monte Rosa Earnings per Share Projection vs Actual
Actual Earning per Share of Monte Rosa refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Monte Rosa Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Monte Rosa, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Monte Rosa Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Monte Rosa, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Monte Rosa should always be considered in relation to other companies to make a more educated investment decision.Monte Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Monte Rosa's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-12-31 | 2024-12-31 | 0.0269 | 0.27 | 0.2431 | 903 | ||
2024-11-07 | 2024-09-30 | -0.4709 | -0.29 | 0.1809 | 38 | ||
2024-08-08 | 2024-06-30 | -0.5408 | -0.43 | 0.1108 | 20 | ||
2024-05-09 | 2024-03-31 | -0.57 | -0.53 | 0.04 | 7 | ||
2024-03-14 | 2023-12-31 | -0.33 | -0.58 | -0.25 | 75 | ||
2023-11-09 | 2023-09-30 | -0.72 | -0.7 | 0.02 | 2 | ||
2023-08-10 | 2023-06-30 | -0.7 | -0.71 | -0.01 | 1 | ||
2023-05-11 | 2023-03-31 | -0.68 | -0.65 | 0.03 | 4 | ||
2023-03-16 | 2022-12-31 | -0.62 | -0.63 | -0.01 | 1 | ||
2022-11-10 | 2022-09-30 | -0.6 | -0.58 | 0.02 | 3 | ||
2022-08-11 | 2022-06-30 | -0.54 | -0.57 | -0.03 | 5 | ||
2022-05-11 | 2022-03-31 | -0.52 | -0.51 | 0.01 | 1 | ||
2022-03-29 | 2021-12-31 | -0.5 | -0.93 | -0.43 | 86 | ||
2021-11-10 | 2021-09-30 | -0.44 | -0.43 | 0.01 | 2 | ||
2021-08-12 | 2021-06-30 | -0.4 | -3.63 | -3.23 | 807 | ||
2021-06-25 | 2021-03-31 | 0 | -3.06 | -3.06 | 0 | ||
2021-03-31 | 2020-12-31 | 0 | -7.1822 | -7.1822 | 0 | ||
2020-03-31 | 2019-12-31 | 0 | -3.0376 | -3.0376 | 0 |
Monte Rosa Corporate Management
| Filip MD | Chief Officer | Profile | |
| Jennifer Champoux | VP Operations | Profile | |
| Sharon Townson | Chief Officer | Profile | |
| Edmund Dunn | Senior Controller | Profile | |
| John Castle | Chief Scientist | Profile | |
| Magnus DPHIL | Senior Development | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Monte Rosa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Monte Rosa. If investors know Monte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Monte Rosa listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Monte Rosa Therapeutics is measured differently than its book value, which is the value of Monte that is recorded on the company's balance sheet. Investors also form their own opinion of Monte Rosa's value that differs from its market value or its book value, called intrinsic value, which is Monte Rosa's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Monte Rosa's market value can be influenced by many factors that don't directly affect Monte Rosa's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Monte Rosa's value and its price as these two are different measures arrived at by different means. Investors typically determine if Monte Rosa is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Monte Rosa's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.